IFNA2 and cryohydrocytosis: The rationale for adding SAMe to pegIFNα/ribavirin treatments is based on our previous analysis of HCV interference with IFNα signaling in cultured cells, transgenic mice and liver biopsies from patients with CHC [6], [8], [9], [13], [21].